LIPO
Price:
$3.162
Market Cap:
$3.82M
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2022-12-19
Stock Exchange
NASDAQ
Ticker
LIPO
According to Lipella Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.74. This represents a change of -88.75% compared to the average of -6.58 of the last 4 quarters.
The mean historical PE Ratio of Lipella Pharmaceuticals Inc. over the last ten years is -221.12. The current -0.74 PE Ratio has changed -66.53% with respect to the historical average. Over the past ten years (40 quarters), LIPO's PE Ratio was at its highest in in the March 2023 quarter at 2.21. The PE Ratio was at its lowest in in the December 2022 quarter at -99.11.
Average
-221.12
Median
-55.40
Minimum
-529.30
Maximum
-10.61
Discovering the peaks and valleys of Lipella Pharmaceuticals Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 214.05%
Maximum Annual PE Ratio = -10.61
Minimum Annual Increase = -96.42%
Minimum Annual PE Ratio = -529.30
Year | PE Ratio | Change |
---|---|---|
2023 | -10.61 | -80.86% |
2022 | -55.40 | 214.05% |
2021 | -17.64 | -96.42% |
2020 | -492.64 | -6.93% |
The current PE Ratio of Lipella Pharmaceuticals Inc. (LIPO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-27.88
5-year avg
-221.12
10-year avg
-221.12
Lipella Pharmaceuticals Inc.’s PE Ratio is less than Senti Biosciences, Inc. (-0.27), greater than Fennec Pharmaceuticals Inc. (-140.49), less than Monopar Therapeutics Inc. (-0.59), less than Applied Molecular Transport Inc. (-0.43), less than Adynxx, Inc. (0), less than Ascletis Pharma Inc. (0), greater than Eupraxia Pharmaceuticals Inc. (-11.53), greater than AVAX Technologies, Inc. (-6.61), less than Transgene SA (-0.00), greater than Alpha Cognition Inc. (-1.81), greater than ImmuCell Corporation (-2.34), less than Anebulo Pharmaceuticals, Inc. (-0.05), greater than NervGen Pharma Corp. (-5.30), greater than Acrivon Therapeutics, Inc. Common Stock (-9.10), greater than Protagenic Therapeutics, Inc. (-3.08), less than Miromatrix Medical Inc. (-0.39), greater than Eliem Therapeutics, Inc. (-7.13), less than Inhibrx Biosciences, Inc. (0), less than Merrimack Pharmaceuticals, Inc. (0.14), greater than Celcuity Inc. (-8.92), greater than Enliven Therapeutics, Inc. (-5.71), greater than null (-13.11),
Company | PE Ratio | Market cap |
---|---|---|
-0.27 | $19.13M | |
-140.49 | $169.78M | |
-0.59 | $116.38M | |
-0.43 | $11.01M | |
0 | $600.00 | |
0 | $242.35M | |
-11.53 | $108.29M | |
-6.61 | $6.89K | |
-0.00 | $209.81M | |
-1.81 | $35.66M | |
-2.34 | $41.08M | |
-0.05 | $42.01M | |
-5.30 | $152.57M | |
-9.10 | $193.98M | |
-3.08 | $3.34M | |
-0.39 | $92.95M | |
-7.13 | $342.68M | |
0 | $209.76M | |
0.14 | $223.97M | |
-8.92 | $465.23M | |
-5.71 | $1.13B | |
-13.11 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lipella Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lipella Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Lipella Pharmaceuticals Inc.'s PE Ratio?
How is the PE Ratio calculated for Lipella Pharmaceuticals Inc. (LIPO)?
What is the highest PE Ratio for Lipella Pharmaceuticals Inc. (LIPO)?
What is the 3-year average PE Ratio for Lipella Pharmaceuticals Inc. (LIPO)?
What is the 5-year average PE Ratio for Lipella Pharmaceuticals Inc. (LIPO)?
How does the current PE Ratio for Lipella Pharmaceuticals Inc. (LIPO) compare to its historical average?